Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR1 amp Pazopanib uterine carcinosarcoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02203760 Phase II Pazopanib Gemcitabine + Pazopanib Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble) Unknown status DEU 0
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT03241745 Phase II Nivolumab A Study of Nivolumab in Selected Uterine Cancer Patients Active, not recruiting USA 0
NCT03485729 Phase II ONC201 ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer Active, not recruiting USA 0
NCT03555422 Phase III Selinexor Maintenance With Selinexor/Placebo After Combination Chemotherapy in Endometrial Cancer [SIENDO] (SIENDO) Active, not recruiting USA | ITA | ESP | DEU | CAN | BEL 4
NCT03603184 Phase III Atezolizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd) Active, not recruiting NZL | ITA | GBR | ESP | DEU | AUT | AUS 4
NCT03651206 Phase II Paclitaxel + Pegylated liposomal doxorubicin + Topotecan Doxorubicin + Gemcitabine + Paclitaxel Niraparib Dostarlimab-gxly + Niraparib Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN) Active, not recruiting FRA 0
NCT03668340 Phase II Adavosertib AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Active, not recruiting USA 0
NCT03694262 Phase II Atezolizumab + Bevacizumab + Rucaparib The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) Completed USA 0
NCT03832361 Phase II Mirvetuximab Soravtansine Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer Recruiting USA 0
NCT04106414 Phase II Nivolumab Linrodostat + Nivolumab Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment Active, not recruiting USA 0
NCT04235101 Phase I Niraparib + Trastuzumab Duocarmazine Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors Completed NLD | GBR | BEL 0
NCT04513665 Phase II ZW25 ZW25 in Women With Endometrial Cancers Completed USA 0
NCT04634877 Phase III Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 19
NCT04906382 Phase I Carboplatin + Paclitaxel + Tislelizumab Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer Terminated USA 0
NCT04969887 Phase II Ipilimumab + Nivolumab Combination Immunotherapy in Rare Cancers Under InvesTigation (MOST-CIRCUIT) Active, not recruiting NZL | AUS 0
NCT05147558 Phase II Lenvatinib + Pembrolizumab A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma Recruiting USA 0
NCT05156268 Phase II Olaparib + Pembrolizumab A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma Recruiting USA 0
NCT05173987 Phase III Cisplatin + Docetaxel Carboplatin + Docetaxel Carboplatin + Paclitaxel Cisplatin + Paclitaxel Pembrolizumab Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) Active, not recruiting USA | NZL | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS 17
NCT05229601 Phase I HFB301001 A Study of HFB301001 in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05255653 Phase II Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) Recruiting NLD | GBR | FRA | CAN 0
NCT05256225 Phase II Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Carboplatin + Paclitaxel Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma Recruiting USA 1
NCT05300048 Phase I Serabelisib Nab-paclitaxel + Serabelisib Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Active, not recruiting USA 0
NCT05559879 Phase Ib/II Cabozantinib + Dostarlimab-gxly Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma Recruiting USA 0
NCT05605509 Phase II Fluorouracil + Irinotecan + Leucovorin + RP-6306 RP-6306 + Trastuzumab Gemcitabine + RP-6306 RP-6306 in Patients With Advanced Cancer Recruiting CAN 0
NCT05611931 Phase III Selinexor Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) Recruiting USA | ITA | ESP | CAN | BEL | AUS 6
NCT05619913 Phase II Eribulin Eribulin + Pembrolizumab EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma (EPOCH) Recruiting GBR | CAN | AUS 0
NCT06132958 Phase III Paclitaxel Doxorubicin SKB264 MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) Recruiting USA | ESP | AUS 3